ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,079.44
0.18%
US Tech 100
17,092.00
0.52%
Dow Jones
38,477.02
-0.07%
Brent Oil
87.15
-0.47%
Bitcoin
65,934.14
-0.74%
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Lexicon Pharmaceuticals Inc (LXRX) Quote

Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc (LXRX)

NASDAQ
1.61
-0.10
(-5.85%)
Closed April 23 4:00PM
Delayed by 15 minutes
1.64
0.03
( 1.86% )
Pre Market: 9:15AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.64
Bid
1.63
Ask
1.66
Volume
4,620
0.00 Day's Range 0.00
0.92 52 Week Range 3.789
Market Cap
394.329M
Previous Close
1.61
Open
-
Last Trade
121
@
1.64
(formt)
Last Trade Time
09:10:03
Financial Volume
-
VWAP
-
Average Volume (3m)
4,720,987
Shares Outstanding
244,924,695
Dividend Yield
-
PE Ratio
-2.23
Earnings Per Share (EPS)
-0.72
Revenue
1.2M
Net Profit
-177.12M

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for ... Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.lexpharma.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Lexicon Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LXRX. The last closing price for Lexicon Pharmaceuticals was $1.61. Over the last year, Lexicon Pharmaceuticals shares have traded in a share price range of $ 0.92 to $ 3.789.

Lexicon Pharmaceuticals currently has 244,924,695 shares outstanding. The market capitalization of Lexicon Pharmaceuticals is $394.33 million. Lexicon Pharmaceuticals has a price to earnings ratio (PE ratio) of -2.23.

LXRX Latest News

More News

Lexicon Pharmaceuticals to Host 2024 Investor Day

THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the...

April 18 2024
GlobeNewswire Inc.

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner...

April 03 2024
GlobeNewswire Inc.

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two...

March 25 2024
GlobeNewswire Inc.

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

THE WOODLANDS, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial...

March 12 2024
GlobeNewswire Inc.

Form PRE 14A - Other preliminary proxy statements

March 11 2024
Edgar (US Regulatory)

Form 8-K - Current report

March 11 2024
Edgar (US Regulatory)

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Commercial launch of INPEFA® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a...

March 11 2024
GlobeNewswire Inc.

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a securities purchase agreement (the...

March 11 2024
GlobeNewswire Inc.

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

Preparations Underway for Resubmission of New Drug Application for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in Patients with Type 1 Diabetes and Chronic Kidney Disease...

March 11 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

February 29 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.08-4.65116279071.721.85751.5939800901.64305539CS
4-0.36-1822.471.5931891261.94258364CS
12-0.16-8.888888888891.83.731.5947209872.4595216CS
260.5347.74774774771.113.730.9236071552.03462475CS
52-0.89-35.17786561262.533.7890.9229755572.05346868CS
156-3.33-67.00201207244.976.32990.9215045602.48088602CS
260-4.22-72.01365187715.869.650.9219222873.23377364CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.35
(0.00%)
161
AADRAdvisorShares Dorsey Wright ADR ETF
$ 61.09
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.84
(0.00%)
3
AACIArmada Acquisition Corporation I
$ 11.27
(0.00%)
1.45k
AACGATA Creativity Global
$ 0.8906
(0.00%)
224
AAGRAfrican Agriculture Holdings Inc
$ 0.35
(0.00%)
161
AADRAdvisorShares Dorsey Wright ADR ETF
$ 61.09
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.84
(0.00%)
3
AACIArmada Acquisition Corporation I
$ 11.27
(0.00%)
1.45k
AACGATA Creativity Global
$ 0.8906
(0.00%)
224
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.1523
(0.00%)
31.23M
CYNCYNGN Inc
$ 0.114
(0.00%)
18.05M
AMSTAmesite Inc
$ 2.00
(0.00%)
12.96M
PEGYPineapple Energy Inc
$ 0.0566
(0.00%)
11.46M
BOFBranchOut Food Inc
$ 1.17
(0.00%)
9.13M

LXRX Discussion

View Posts
BooDog BooDog 6 days ago
Almost added back in but want to see confirmation for bottom. Double bottoms can be tricky. But even so, long term I like this.
👍️0
BooDog BooDog 1 week ago
Zacks analysis.
https://www.zacks.com/stock/news/2256264/all-you-need-to-know-about-lexicon-lxrx-rating-upgrade-to-buy

Upgrading to buy while I'm watching for the gap to fill which may put this around 1.40's. We'll see. I think analysts are always late to the party but this report is actually pretty timely.
👍️0
BooDog BooDog 3 weeks ago
Quite the gap there if that's what you're looking at.
👍️0
glenn1919 glenn1919 4 weeks ago
LXRX.......................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
dcaf7 dcaf7 1 month ago
Lexicon will resubmit an NDA for sotagliflozin for patients with type 1 diabetes and chronic kidney disease. Good news. FDA rejected an NDA for type 1 diabetes in 2019. Now they changed their mind but only for patients with T1D+CKD. According to today's company presentation, slide 10, this population makes 21% of adults with T1D, or ~357,000 patients. Not a big addition to current indication. However, it will be the first gliflozin approved for T1D. No competition.
👍️ 1
Awl416 Awl416 1 month ago
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
👍️0
BooDog BooDog 2 months ago
Earnings expected next Thursday, a miss or a hit? Revenue a hit imo.

Form 4 filed
👍️0
jdheart101 jdheart101 2 months ago
200 July 2.5 calls @.88 . Be back soon !!!
👍️0
TIMGZ TIMGZ 2 months ago
INBS**** AS ALWAYS SUPER FAST COMPUTERS***WHALES***HEDGES FUNDS*** TRADERS MIGHT SURGE THE VOLUME AT A VERY HIGH FREQUENCY****


WITHIN MINUTES*****UPTREND

SEEMS SETTING UP NICELY FOR THAT
👍️0
BooDog BooDog 2 months ago
Still looking pretty good here. Did trim a few 2.38's thouigh. Not sure if we'll see a reset soon or not.

👍️0
glenn1919 glenn1919 3 months ago
LXRX..........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
jdheart101 jdheart101 3 months ago
Another 4000. @1.76
👍️0
Legend431 Legend431 3 months ago
Oops
👍️0
jdheart101 jdheart101 3 months ago
I’m in today 9500 @1.49 1/23/24
👍️0
BooDog BooDog 5 months ago
Ready to see this rock and roll. Get the Christmas rally going!

https://www.inpefahcp.com/


Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. Wikipedia
Stock price: LXRX (NASDAQ) $1.16 +0.01 (+1.32%)
Dec 6, 10:18?AM EST - Disclaimer
Headquarters: The Woodlands, TX
CEO: Lonnel Coats (Jul 7, 2014–)
Revenue: 324.1 million USD (2019)
Number of employees: 225 (2011)
Founded: 1995, The Woodlands, TX
Founder: Arthur T Sands
Subsidiaries: Lex-Gen Woodlands, L.P., Lexicon Pharmaceuticals (New Jersey), Inc
Product
https://www.lexpharma.com/

https://www.lexpharma.com/media-center/news
👍️0
BooDog BooDog 5 months ago
Insider buying... Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc

https://finance.yahoo.com/news/director-philippe-amouyals-strategic-200-060356510.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW52aXouY29tLw&guce_referrer_sig=AQAAAIoi6pMjBlhAAWCTqsgFDgJ_L3Mq27MaOD9VoCvqo193rq8IznDFhr2okgZCfdpTcOoOQpbq-htdQ0dRd_C7SPjLqq1-XLfxoxxNvrWLXCfYfWwGJkWm40NnRnChJ7IS-3NNjcnArKcxghtaIU9gZcRtqotAVRnZUPj9phWfJymM
👍️0
Monksdream Monksdream 5 months ago
LXRX new 52 week low
👍️0
BooDog BooDog 6 months ago
$LXRX. Looking good. See this in a week or 2.

JMHO.
👍️0
glenn1919 glenn1919 6 months ago
LXRX................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
TRADER99 TRADER99 6 months ago
Looks like we saw a bottom here with this spike in volume
👍️0
Monksdream Monksdream 7 months ago
LXRX new 52 week low
👍️0
BooDog BooDog 7 months ago
Guess I wasn't watching the board here Monk. Have been watching the chart though and have been accumulating around 1.10' last week and added today.

Cheers
👍️0
Monksdream Monksdream 7 months ago
LXRX new 52 week low
👍️0
Monksdream Monksdream 7 months ago
LXRX new 52 week low
👍️0
Monksdream Monksdream 7 months ago
LXRX new 52 week low
👍️0
Monksdream Monksdream 7 months ago
LXRX new 52 week low
👍️0
BooDog BooDog 9 months ago
LXRX 1.70's. Watching.
👍️0
BooDog BooDog 10 months ago
$LXRX https://finance.yahoo.com/news/lexicon-announces-planned-advancement-lx9211-004500120.html
Conference call this morning...

Conference Call and Webcast Information

Lexicon management will hold a live conference call and webcast Monday, June 26, 2023, at 8:00 am ET / 7:00 am CT. The dial-in number for the conference call is 888-317-6003 and the conference ID for all callers is 7186279. The live webcast and replay may be accessed by visiting Lexicon’s website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.
👍️0
BooDog BooDog 11 months ago
👍️0
BooDog BooDog 11 months ago
Quite the boost for institutionals.
https://www.sec.gov/Archives/edgar/data/1062822/000119312523160877/d449914dsc13da.htm
👍️0
BooDog BooDog 11 months ago
Agree. Too easy here. So predictable they'd be doing an offering though. Easy peasy this one is.
Taking nibbles in the 2.50's. Should have sold more on the highs yesterday.
👍️0
TIMGZ TIMGZ 11 months ago
LXRX MIGHT NOT BE LOOKING BACK AGAN, FDA APPROVED DRUG AND ALL BIG PHARMA EYEING. MY OPINION *******
ONE PAID $260M FOR BACKING OUT, NOW LOOK AT LXRX
👍️ 1
BooDog BooDog 11 months ago
2.75 support. See how it holds, or not. Interesting sell off.
👍️0
glenn1919 glenn1919 11 months ago
LXRX.........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
BooDog BooDog 11 months ago
Hey there Glenn. This puppy has been excellent. Certainly one to keep an eye on.
👍️0
glenn1919 glenn1919 11 months ago
LXRX...........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
BooDog BooDog 11 months ago
If I se what I think I see, there's a reason shorts are leaving this puppy alone.

Added back in this morning but when something starts really moving you always say in hindsight that you should have bought more.
👍️0
glenn1919 glenn1919 12 months ago
LXRX.............................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
BooDog BooDog 12 months ago
High 2.96. Trip and rip potential. That's when the chart show either a tripple bottom or a tripple top and breaks through with some serious momentum.

See what this puppy does.


https://www.barchart.com/stocks/quotes/hils/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=LXRX&grid=1&height=210&studyheight=100
👍️0
BooDog BooDog 1 year ago
Passing 2.69.
👍️0
BooDog BooDog 1 year ago
Let's get the move on.
👍️0
BooDog BooDog 1 year ago
PUDUFA coming in a couple months. Looks like they're pretty confident.

GLTA
👍️0
makinezmoney makinezmoney 1 year ago
$LXRX: Time to load July $3 calls...... now $0.70

Why ????

1. Cash on Hand.............. $138.4Milly
2. Huge Insider buying of shares of $45Milly at $2.50sh
3. Piper Sandler with $10 Overweight assigned back in August last year
4. PDUFA coming in MAY
5. Largest OI is 1k on the July $3 calls


You know what that means right ???? They gotta a good feeling about that PDUFA
$LXRX now at $2.44......... last time it spiked ffrom $1.12 to $9.50 from Nov6,2020 to
Feb1, 2021 ..... 9x bagger !

Round 2 coming


GO $LXRX
👍️0
BooDog BooDog 1 year ago
Chart showing some strength. Closes over 2.20 and the bulls will be in the lead for next week imo.

LXRX daily
👍️0
BooDog BooDog 1 year ago
Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022

THE WOODLANDS, Texas, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in Munich, Germany:

“Evaluation of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain: Study Design and Topline Results from the RELIEF-DPN-1 Trial”, describes the positive results achieved in this proof-of-concept study and will be given on Saturday, October 29th at 3:25pm CEST/9:25am ET.


“Evaluation of LX9211, a Potent, Selective Inhibitor of AAK1, in Preclinical Models of Spasticity”, describes the effect of LX9211 in reducing spasticity in established animal models and will be given on Monday, October 31st at 3:35pm CET/8:35am ET.


https://finance.yahoo.com/news/lexicon-pharmaceuticals-announces-oral-presentations-125900260.html


Looks to be waking up.

LXRX chart
👍️0
BooDog BooDog 2 years ago
Bears are on the job. eom


LXRX chart

Message in reply to:
Bear flag forming. And right before the golden cross. Waiting to add.

Thinking 2.45 - 2.50 support may hold. Though depending on what really happens the $2 support looks stronger.

I'm looking for around $2. This looks like it's only starting to crack. Of course, news AND SOME VOLUME!!!! would certainly help.

No one answered me about the bear flag. So not sure if anyone did anything.
👍️0
BooDog BooDog 2 years ago
Bear flag forming. And right before the golden cross. Waiting to add.

Thinking 2.45 - 2.50 support may hold. Though depending on what really happens the $2 support looks stronger.

LXRX daily


All imo of course.
👍️0
BooDog BooDog 2 years ago
Nice to see the volume maintaining. Hope some were able to take advantage advantage of the dip.
👍️0
BooDog BooDog 2 years ago
Nice!! Get'r done LXRX!
👍️0
BooDog BooDog 2 years ago
Watching the reset. Told you this a great swing play stock.
👍️0

Your Recent History

NASDAQ
LXRX
Lexicon Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved